This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.

Accept

Asia-Pacific

  1. If we can't name the problem, we can't defeat it. Enter PATH's initiative to defeat diarrheal disease.
    Published: November 2021
    Type: Article
  2. In Vietnam, the USAID/PATH Healthy Markets project is engaging pharmacies and e-commerce in the delivery of HIV self-testing, pre-exposure prophylaxis, and other health care products. These partnerships have proved invaluable for maintaining access to essential HIV and primary health care services as the country battles increasingly complex and prolonged waves of COVID-19.
    Published: November 2021
    Type: Resource Page
  3. Rotavirus is the leading cause of severe and fatal diarrhea in young children worldwide, but vaccines can stop this deadly disease.
    Published: November 2021
    Type: Article
  4. Global convening of syringe manufacturers and multilateral organizations held to help bolster supply.
    Published: November 2021
    Type: Press Release
  5. This document, current as of November 11, 2021, provides data and information from PATH's COVID-19 modeling focused on the global autodisable (AD) syringe supply gap. This current forecast shows a gap of more than 1 billion safety syringes that could impact immunization efforts in 100 countries. The AD syringe gap analysis combines syringe supply capacity collected from manufacturers with estimated syringe demand from all countries known to use AD syringes globally, including demand for both COVID-19 and non-COVID-19 immunizations. The demand forecast for COVID-19 vaccination syringes is based on projected vaccine availability through the end of 2022 and includes secured bilateral deals, COVAX deals, donations, and other multilateral deals.
    Published: November 2021
    Type: Resource Page
  6. Promising new vaccines against the leading bacterial causes of diarrhea use a detail-oriented approach to battle these bugs.
    Published: November 2021
    Type: Article
  7. Listed are a web page and fact sheet (Chinese and English translations) summarizing and linking to the offerings included in a training series developed by PATH entitled "Global Access Training for Chinese COVID-19 Vaccine Developers." The training is designed to provide an overview of key vaccine development strategies and planning necessary to develop COVID-19 vaccines that meet World Health Organization prequalification requirements and are competitive in the global market.
    Published: November 2021
    Type: Resource Page
  8. Nipah virus has pandemic and bioterrorism potential. A vaccine candidate is undergoing Phase 1 trial.
    Published: November 2021
    Type: Article
  9. Current live, oral rotavirus vaccines (LORVs) are reducing severe diarrhea in all settings, but they are not as effective in places with the highest burden. Alternative approaches in advanced clinical development include injectable next-generation rotavirus vaccines (iNGRVs), which have the potential to better protect children against disease, be combined with existing routine immunizations, and be even more affordable than the current LORVs. PATH conducted a series of studies to understand the real public health value of iNGRVs to help inform decisions by international agencies, funders, vaccine manufacturers, and countries. This included a feasibility and acceptability study with national stakeholders and healthcare providers in Ghana, Kenya, Malawi, Peru, Senegal, and Sri Lanka to assess their preferences for different hypothetical rotavirus vaccine options. These briefs provide an overview of the results in each of the study countries.
    Published: October 2021
    Type: Resource Page
  10. Current live, oral rotavirus vaccines (LORVs) are reducing severe diarrhea in all settings, but they are not as effective in places with the highest burden. Alternative approaches in advanced clinical development include injectable next-generation rotavirus vaccines (iNGRVs), which have the potential to better protect children against disease, be combined with existing routine immunizations, and be even more affordable than the current LORVs. PATH conducted a series of studies to understand the real public health value of iNGRVs to help inform decisions by international agencies, funders, vaccine manufacturers, and countries. This included: targeted analyses on the ideal age group for iNGRVs and potential future combination vaccine options, impact and cost effectiveness analyses, a feasibility and acceptability study with national stakeholders and healthcare providers in six countries, and a demand forecast. This brief provides a comprehensive summary of the results.
    Published: October 2021
    Type: Resource Page
Load more